Matthew Feldman
Allergy & Immunology · Dallas, TXNPI 1104056027
Payments from drug & device makers
Across 902 payments — averaging $454.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$174K
- Sanofi$156K
- GSK$31K
- Regeneron$18K
- Dermavant Sciences, Inc.$11K
- Organon$6K
- plus $13K from 31 others
What the payments were for
- Consulting fees$60,03915%
- Speaking & faculty fees$298,07373%
- Travel & lodging$34,0418%
- Food & beverage$17,6424%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 242 | $174,136 |
| Sanofi | 178 | $155,696 |
| GSK | 90 | $31,492 |
| Regeneron | 17 | $18,285 |
| Dermavant Sciences, Inc. | 8 | $10,718 |
| Organon | 18 | $6,206 |
| Genentech USA, Inc. | 18 | $4,376 |
| AstraZeneca | 121 | $2,392 |
| AbbVie | 5 | $2,085 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $498 |
| Grifols USA, LLC | 20 | $372 |
| Sanofi-aventis U.S. LLC | 6 | $335 |
| Novartis | 15 | $319 |
| CSL Behring | 13 | $285 |
| Pfizer | 13 | $284 |
| Kaleo, Inc. | 11 | $240 |
| Pharming Healthcare, Inc. | 12 | $240 |
| Teva Pharmaceuticals USA, Inc. | 13 | $225 |
| Optinose US, Inc. | 11 | $208 |
| Amgen | 8 | $187 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $177 |
| Galderma Laboratories, L.p. | 10 | $147 |
| Octapharma USA, Inc. | 3 | $146 |
| Lilly USA, LLC | 3 | $89 |
| LEO Pharma Inc. | 3 | $81 |
| Alk-abello, Inc | 4 | $80 |
| Covis Pharma GmbH | 4 | $78 |
| Biocryst US Sales Co., LLC | 4 | $77 |
| Boehringer Ingelheim | 4 | $76 |
| Shire North American Group Inc | 4 | $68 |
| Azurity Pharmaceuticals, Inc. | 3 | $63 |
| Hospira, Inc. | 3 | $57 |
| GC Biopharma USA, Inc. | 2 | $52 |
| Hikma Pharmaceuticals USA | 3 | $52 |
| Blueprint Medicines Corporation | 2 | $47 |
| Incyte Corporation | 2 | $37 |
| Biocryst Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$409,927 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 29 | $111,355 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,926 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,017 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,324 |
| Ipratropium Bromide | 23 | $675 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $475 |
| Fluticasone Propionate | 14 | $300 |
| Montelukast Sodium | 22 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $31,492 | $13,92618 claims |
| AstraZenecaSymbicort | $2,392 | $4,01711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Barbara BaxterDallas$2.5M
- Richard WassermanDallas$1.9M
- Elliot GinchanskyDallas$477K
- Lara GrossDallas$171K
- Anil NandaDallas$86K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Lyndon MansfieldEl Paso$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.